Loading...
XKRX
253840
Market cap78mUSD
Dec 05, Last price  
7,070.00KRW
1D
-1.12%
1Q
1.14%
IPO
8.77%
Name

SugenTech Inc

Chart & Performance

D1W1MN
XKRX:253840 chart
P/E
P/S
11.43
EPS
Div Yield, %
Shrs. gr., 5y
4.35%
Rev. gr., 5y
21.30%
Revenues
10.10b
+41.57%
601,109,6181,090,268,1623,439,993,3035,448,790,0673,845,080,64641,351,848,29877,201,041,452101,399,255,8337,132,305,54010,097,083,000
Net income
-15.19b
L-11.87%
-1,511,996,258-1,558,392,021-20,960,485,413-40,915,428,995-9,561,056,493-41,018,413,35936,151,559,44026,716,630,860-17,238,284,500-15,192,705,000
CFO
-7.52b
L-38.15%
-1,197,283,537-1,335,399,006-909,594,013-3,134,053,492-4,011,329,34614,332,738,08638,955,129,42730,427,994,726-12,153,244,980-7,517,117,000
Dividend
Dec 27, 2023150 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers Multiplex BLOT disease diagnostic devices, such as immunoblot processor, semi and full automation, and molecular diagnostic systems, as well as test items; and self-testing products, including digital ovulation, pregnancy test, and early sign pregnancy test, as well as mobile testing products. It also provides point of care testing analyzers and test items for testing of M.tuberculosis, M.bovis, SARS-CoV-2 antibodies and antigens, flu A/B antigens, and CRP/hsCRP /dualCRP, as well as for measuring procalcitonin, troponin I, hemoglobinA1c, human chorionic gonadotropin, immunoglobulin E, and influenza A/B. The company was formerly known as Accugen Healthcare, Inc. and changed its name to Sugentech Inc. in October 2013. Sugentech Inc. was founded in 2011 and is headquartered in Daejeon, South Korea.
IPO date
Nov 11, 2016
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT